<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630693</url>
  </required_header>
  <id_info>
    <org_study_id>MA38</org_study_id>
    <nct_id>NCT02630693</nct_id>
  </id_info>
  <brief_title>Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer</brief_title>
  <official_title>Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of endocrine therapy and
      Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer
      dose interruptions than the proposed dosing regimen of 125 mg daily for 21 days out of a 28
      day cycle in combination with endocrine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard or usual treatment of this type of breast cancer is endocrine therapy.
      Palbociclib is a new type of drug for breast cancer. Laboratory tests as well as studies in
      animals and people show that it may help slow the growth of breast cancer. The most widely
      tested regimen of Palbociclib for patients with metastatic/advanced breast cancer is 125 mg
      every day for 21 days out of a 28 day cycle in combination with standard endocrine (hormone)
      therapy. This study explores if administering a lower dose of palbociclib - 100 mg given
      every day of a 28 day cycle in combination with standard endocrine (hormone) therapy - may
      result in more tumour shrinkage and be better tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2015</start_date>
  <completion_date type="Actual">November 16, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Using the RECIST 1.1 Criteria</measure>
    <time_frame>2 years</time_frame>
    <description>progression free survival (PFS) is defined as time from randomization to progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response or No Response</measure>
    <time_frame>2 years</time_frame>
    <description>Response rate = Number of (Complete response + partial response) / total treated patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years</time_frame>
    <description>For patients with complete or partial response, duration of response is defined as days from first recorded response to the first date of recurrent or progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to death of any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Palbociclib (100mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palbociclib (125mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 100mg</intervention_name>
    <description>100mg PO daily</description>
    <arm_group_label>Palbociclib (100mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg</intervention_name>
    <description>125mg PO daily 3 weeks out of 4</description>
    <arm_group_label>Palbociclib (125mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant or Tamoxifen or Aromatase Inhibitor</intervention_name>
    <description>given at the standard doses/schedules</description>
    <arm_group_label>Palbociclib (100mg)</arm_group_label>
    <arm_group_label>Palbociclib (125mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal and postmenopausal women 18 years of age or older.

          -  Histologically confirmed adenocarcinoma of the breast, with ER positive and HER2
             negative status based on local testing on most recent pathological tumour specimen.

          -  Patients must satisfy the following criteria for prior therapy:

               -  Progressed during treatment or within 12 months of completion of adjuvant
                  endocrine therapy or

               -  Progressed during prior endocrine therapy for advanced/metastatic disease. Note:
                  'Progressed during endocrine therapy' means that the patient progressed while on
                  or within 1 month after discontinuation of endocrine therapy.

          -  One line of chemotherapy for advanced/metastatic disease (regardless of prior adjuvant
             chemotherapy use) is allowed in addition to endocrine therapy.

          -  Patients must have evidence of disease to be eligible for the study, but measurable
             disease is not mandatory.

          -  For those patient with measureable disease who will be included in the response
             assessment, the following criteria must apply:

               -  X-ray ≥ 20 mm

               -  Spiral CT scan or physical exam ≥ 10 mm (lymph nodes must be ≥ 15 mm in the short
                  axis)

               -  Conventional CT scan, MRI ≥ 20 mm

               -  Measurable lesions must be outside a previous radiotherapy field if they are the
                  sole site of disease, unless disease progression has been documented.

        Tumor lesions previously irradiated or subjected to other loco regional therapy will only
        be deemed measurable if progression at the treated site after completion of therapy is
        clearly documented.

          -  Eastern Cooperative Oncology Group (ECOG) 0-2.

          -  Adequate organ and bone marrow function as defined by:

               -  ANC ≥ 1,500/mm3 (1.5 x 109/L)

               -  Platelets ≥ 100,000/mm3 (100 x 109/L)

               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥60 ml/min as
                  calculated using the method standard for the institution;

               -  Total serum bilirubin ≤ 1.5 x ULN (&lt;3 ULN if Gilbert's disease).

          -  Patient must agree to provide tumour tissue from the most recent pathological tumour
             specimen.

          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life
             questionnaires in either English or French

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrollment in
             the trial to document their willingness to participate

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre. This implies there
             must be reasonable geographical limits placed on patients being considered for this
             trial.

          -  In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working
             days of patient randomization.

          -  Women of childbearing potential must have agreed to use a highly effective
             contraceptive method.

        Exclusion Criteria:

          -  Patients with advanced, symptomatic, visceral spread that are at risk of life
             threatening complication in the short term.

          -  Patients with symptomatic CNS involvement, meningeal or parenchymal, that is
             uncontrolled or requires steroids.

          -  Prior treatment with any CDK 4/6 inhibitor.

          -  Prior treatment with mTOR inhibitors.

          -  Active second malignancy, regardless of ongoing treatment.

          -  Any concurrent medical condition that in the opinion of the investigator would
             interfere with the safe administration of the study drug and participation in the
             study.

          -  Participation in a prior anti-cancer investigational study within 30 days prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil A. Joy</last_name>
    <role>Study Chair</role>
    <affiliation>Cross Cancer Institute, Edmonton Alberta Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Abbotsford Centre</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>February 20, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02630693/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02630693/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Palbociclib (100mg)</title>
          <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
        <group group_id="P2">
          <title>Palbociclib (125mg)</title>
          <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline variables were reported using intend to treat principle</population>
      <group_list>
        <group group_id="B1">
          <title>Palbociclib (100mg)</title>
          <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
        <group group_id="B2">
          <title>Palbociclib (125mg)</title>
          <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="B2" value="59.5" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="B3" value="60.5" lower_limit="53" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Using the RECIST 1.1 Criteria</title>
        <description>progression free survival (PFS) is defined as time from randomization to progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>2 years</time_frame>
        <population>Intend to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib (100mg)</title>
            <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib (125mg)</title>
            <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Using the RECIST 1.1 Criteria</title>
          <description>progression free survival (PFS) is defined as time from randomization to progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>Intend to treat population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" lower_limit="6.93" upper_limit="13.90"/>
                    <measurement group_id="O2" value="11.30" lower_limit="8.08" upper_limit="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>As stated in the protocol, the primary objective of this trial is to estimate the hazard ratio and the corresponding 90% confidence interval. Therefore, we do not conduct any statistical hypothesis test for progression free survival.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Hazard ratio of Palbociclib100mg arm vs 125 mg arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response or No Response</title>
        <description>Response rate = Number of (Complete response + partial response) / total treated patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>2 years</time_frame>
        <population>Only patients received protocol treatment were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib (100mg)</title>
            <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib (125mg)</title>
            <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response or No Response</title>
          <description>Response rate = Number of (Complete response + partial response) / total treated patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Only patients received protocol treatment were included in this analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>For patients with complete or partial response, duration of response is defined as days from first recorded response to the first date of recurrent or progression or death.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib (100mg)</title>
            <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib (125mg)</title>
            <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>For patients with complete or partial response, duration of response is defined as days from first recorded response to the first date of recurrent or progression or death.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="88" upper_limit="251"/>
                    <measurement group_id="O2" value="169" lower_limit="82" upper_limit="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from randomization to death of any cause.</description>
        <time_frame>2 years</time_frame>
        <population>Intend to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib (100mg)</title>
            <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib (125mg)</title>
            <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from randomization to death of any cause.</description>
          <population>Intend to treat population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.73" lower_limit="19.29" upper_limit="23.30"/>
                    <measurement group_id="O2" value="21.39" lower_limit="19.65" upper_limit="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>As stated in the protocol, the objective of this trial is to estimate the hazard ratio and the corresponding 90% confidence interval. Therefore, we do not conduct any statistical hypothesis test for overall survival.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>Hazard ratio for Palbociclib 100mg arm vs 125 mg arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Palbociclib (100mg)</title>
          <description>Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 100mg: 100mg PO daily
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
        <group group_id="E2">
          <title>Palbociclib (125mg)</title>
          <description>Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
Palbociclib 125mg: 125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor: given at the standard doses/schedules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other general disorders, administration site conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Other hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other renal and urinary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other eye disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="90"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="90"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="90"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="90"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="90"/>
                <counts group_id="E2" events="73" subjects_affected="73" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other infections and infestations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="90"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="90"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="90"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="90"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other musculoskeletal and connective tissue disorder</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="90"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other nervous system disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="90"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="90"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="90"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="90"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="90"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="90"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Other skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="90"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="90"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wendy Parulekar</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>613-533-6430</phone>
      <email>wparulekar@ctg.queenus.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

